Vericel Corporation (VCEL)

Over the past six months, Vericel's stock has experienced fluctuations, reaching a 52-week high of $57.9 in November 2024 and a low of $37.38 in July 2025. Key events impacting the stock include the Q1 2025 earnings report with a wider-than-expected net loss but raised revenue guidance, and the Q2 2025 earnings report showing a revenue increase and narrowed net loss. Analyst ratings have generally been positive, though some price targets have been lowered. FDA approvals for MACI Arthro and NexoBrid for pediatric burn patients have been positive catalysts. Several insiders have engaged in selling shares.

Vericel Corporation has indicated that seasonal sales patterns and other variations related to revenue recognition may cause significant fluctuations in results of operations and cash flows. Specific details on what drives this seasonality for its products were not explicitly provided.

Vericel Corporation is a commercial-stage biopharmaceutical company focused on advanced cell therapies for sports medicine and severe burn care. It operates in the Health Technology sector, specifically in the Pharmaceuticals: Major and Biotechnology: Biological Products industries. The company researches, develops, manufactures, and distributes patient-specific, expanded cellular therapies, including MACI for knee cartilage repair, Epicel for permanent skin replacement in burn patients, and NexoBrid for eschar removal in burn patients.

Vericel Corporation primarily serves the United States and North American markets.

Vericel maintains a strong brand reputation due to its market leadership in cell therapy for sports medicine and burn care. Its innovative products, MACI and Epicel, are backed by FDA approvals, including the expansion of MACI's indication for arthroscopic delivery. The company's focus on regenerative medicine and patient outcomes contributes positively to its standing.

Major institutional investors hold significant stakes in Vericel Corp. In Q1 2025, Capital Research Global Investors increased their holdings, while Brown Capital Management LLC reduced theirs. Geneva Capital Management LLC and Congress Asset Management Co. also added shares in Q1 and Q2 2025, respectively.